CRBP
HealthcareCorbus Pharmaceuticals Holdings, Inc.
$7.83
$-0.04 (-0.51%)
Jan 5, 2026
Price History (1Y)
Analysis
Corbus Pharmaceuticals Holdings, Inc. is a biotechnology company in the healthcare sector with 28 employees. The company's market capitalization stands at $137.44 million. The company's financial performance indicates significant losses, as evidenced by net income of -$67,512,000 and EBITDA of -$75,631,000 over the trailing twelve months. Additionally, free cash flow is also negative at -$37,465,124. However, Corbus Pharmaceuticals has a substantial amount of cash on hand, totaling $103.98 million, while its debt levels are relatively low at $2.05 million. The company's valuation metrics paint a picture of a highly volatile stock with a forward P/E ratio of -1.50 and an EV/EBITDA ratio of -0.48. The 52-week high and low prices indicate significant price fluctuations, with the stock reaching as high as $20.56 and as low as $4.64.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $137.44M
- P/E Ratio
- N/A
- 52-Week High
- $20.56
- 52-Week Low
- $4.64
- Avg Volume
- 473.35K
- Beta
- 2.77
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 28